In conclusion, the armoring of the carcinoma-directed peptide–HLA-I fusion protein EpCAM-ReTARGTPR with IFNαR149A potently enhanced the efficacy of pre-existing anti-CMV CD8pos T-cell immunity to selectively eliminate EpCAMpos cancer cells. Here, EPCAM is linked to carcinoma.